Immunoprecise Stock Performance

IPA -  USA Stock  

USD 5.30  0.15  2.75%

On a scale of 0 to 100, Immunoprecise Antibodies holds a performance score of 3. The company retains a Market Volatility (i.e., Beta) of 1.0079, which attests to a somewhat significant risk relative to the market. Let's try to break down what Immunoprecise's beta means in this case. Immunoprecise Antibodies returns are very sensitive to returns on the market. As the market goes up or down, Immunoprecise Antibodies is expected to follow. Although it is extremely important to respect Immunoprecise Antibodies current price history, it is better to be realistic regarding the information on equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By evaluating Immunoprecise Antibodies technical indicators, you can presently evaluate if the expected return of 0.22% will be sustainable into the future. Please utilizes Immunoprecise Antibodies maximum drawdown, and the relationship between the information ratio and downside variance to make a quick decision on whether Immunoprecise Antibodies current trending patterns will revert.
  
Refresh
Immunoprecise Performance
3 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Immunoprecise Antibodies are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat fragile basic indicators, Immunoprecise Antibodies sustained solid returns over the last few months and may actually be approaching a breakup point. ...more

Immunoprecise Price Channel

Quick Ratio5.10
Fifty Two Week Low3.51
Target High Price11.76
Fifty Two Week High16.47
Target Low Price11.76

Immunoprecise Antibodies Relative Risk vs. Return Landscape

If you would invest  493.00  in Immunoprecise Antibodies on February 27, 2022 and sell it today you would earn a total of  37.00  from holding Immunoprecise Antibodies or generate 7.51% return on investment over 90 days. Immunoprecise Antibodies is generating 0.219% of daily returns assuming volatility of 4.7162% on return distribution over 90 days investment horizon. In other words, 40% of stocks are less volatile than Immunoprecise, and above 96% of all equities are expected to generate higher returns over the next 90 days.
 Daily Expected Return (%) 
      Risk (%) 
Considering the 90-day investment horizon Immunoprecise Antibodies is expected to generate 3.51 times more return on investment than the market. However, the company is 3.51 times more volatile than its market benchmark. It trades about 0.05 of its potential returns per unit of risk. The DOW is currently generating roughly -0.02 per unit of risk.

Immunoprecise Antibodies Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunoprecise Antibodies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunoprecise Antibodies, and traders can use it to determine the average amount a Immunoprecise Antibodies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0464

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small ReturnsIPA
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative Returns
Estimated Market Risk
 4.72
  actual daily
 
 40 %
of total potential
 
4040
Expected Return
 0.22
  actual daily
 
 4 %
of total potential
 
44
Risk-Adjusted Return
 0.05
  actual daily
 
 3 %
of total potential
 
33
Based on monthly moving average Immunoprecise Antibodies is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunoprecise Antibodies by adding it to a well-diversified portfolio.

About Immunoprecise Antibodies Performance

To evaluate Immunoprecise Antibodies Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Immunoprecise Antibodies generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Immunoprecise Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Immunoprecise Antibodies stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Immunoprecise's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Average Assets(0.18) (0.19) 
Return on Average Equity(0.24) (0.26) 
Return on Invested Capital(0.76) (0.82) 
Return on Sales(0.35) (0.38) 
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing B cell sorting, screening, and sequencing custom, immune, and naive phage display production and screening transgenic animals and multi-species antibody discovery bi-specific, tri-specific, VHH, and VNAR antibody manufacturing DNA cloning, protein and antibody downstream processing antibody characterization on label-free biosensors and antibody engineering transient and stable cell line generation antibody optimization and humanization hybridoma production with multiplexed, high-throughput screening, and clone-picking and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Things to note about Immunoprecise Antibodies

Checking the ongoing alerts about Immunoprecise Antibodies for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Immunoprecise Antibodies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Immunoprecise Antibodies Alerts

Equity Alerts and Improvement Suggestions

Immunoprecise Antibodies has very high historical volatility over the last 90 days
Immunoprecise Antibodies was previously known as IMMUNOPRECISE ANTIBODIES LTD and was traded on NASDAQ Exchange under the symbol IPATF.
The company reported the last year's revenue of 19 M. Reported Net Loss for the year was (17.1 M) with profit before taxes, overhead, and interest of 11.4 M.
Immunoprecise Antibodies has about 32.99 M in cash with (8.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.7.
Immunoprecise Antibodies has a poor financial position based on the latest SEC disclosures
Latest headline from www.digitaljournal.com: Biotech Recovery Accelerates These Companies Benefit - Digital Journal
Please see Risk vs Return Analysis. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.